Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

Author's Avatar
Nov 21, 2020
Article's Main Image

- Zokinvy increases survival by 2.5 years in children and young adults with Progeria

- Rare Pediatric Disease Priority Review Voucher issued to Eiger from FDA

- Eiger to host an investor call, November 23, at 8:30 AM ET / 5:30 AM PT

PR Newswire